rs113358486
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.3190+2T>G variant causes a splice donor, intron change. The variant allele was found at a frequency of 0.00000207 in 1,447,602 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000256.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.3190+2T>G | splice_donor_variant, intron_variant | Intron 29 of 34 | 5 | NM_000256.3 | ENSP00000442795.1 | |||
MYBPC3 | ENST00000399249.6 | c.3190+2T>G | splice_donor_variant, intron_variant | Intron 28 of 33 | 5 | ENSP00000382193.2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000837 AC: 2AN: 239022Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 130412
GnomAD4 exome AF: 0.00000207 AC: 3AN: 1447602Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 720550
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:2
- -
Not observed at a significant frequency in large population cohorts (gnomAD); Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 27532257, 23690394, 26914223, 24111713, 29121657, 33673806) -
Hypertrophic cardiomyopathy Pathogenic:2
This sequence change affects a donor splice site in intron 29 of the MYBPC3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is present in population databases (rs113358486, gnomAD 0.002%). Disruption of this splice site has been observed in individuals with hypertrophic cardiomyopathy (PMID: 24111713, 26914223, 27532257). ClinVar contains an entry for this variant (Variation ID: 42691). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
The c.3190+2T>G variant in MYBPC3 has been reported in at least 15 individuals w ith HCM and segregated with disease in 3 affected relatives from 2 families (Ber ge 2014, Walsh 2016, LMM data). It has also been identified in 2/111408 of Europ ean chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadi nstitute.org; dbSNP rs113358486). This variant occurs in the invariant region (+ /- 1,2) of the splice consensus sequence and is predicted to cause altered splic ing leading to an abnormal or absent protein. Heterozygous loss of function of t he MYBPC3 gene is an established disease mechanism in HCM. In summary, this vari ant meets criteria to be classified as pathogenic for HCM in an autosomal domina nt manner based upon predicted splicing impact, case observations, and segregati on studies. ACMG/AMP criteria applied: PVS1, PS4, PM2, PP1. -
Hypertrophic cardiomyopathy 4;C3715165:Left ventricular noncompaction 10 Pathogenic:1
- -
Cardiomyopathy Pathogenic:1
This variant causes a T to G nucleotide substitution at the +2 position of intron 29 of the MYBPC3 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. Although this prediction has not been confirmed in published RNA studies, this variant is expected to result in an absent or disrupted protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 24111713, 26914223, 27532257, 28971120). This variant has been identified in 2/239022 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MYBPC3 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Hypertrophic cardiomyopathy 4 Pathogenic:1
PVS1, PS4, PP3, PP5, BP2 -
Primary familial hypertrophic cardiomyopathy Pathogenic:1
- -
Cardiovascular phenotype Pathogenic:1
The c.3190+2T>G intronic pathogenic mutation results from a T to G substitution two nucleotides after coding exon 29 in the MYBPC3 gene. This alteration has been detected in multiple individuals from cohorts reported to have hypertrophic cardiomyopathy (HCM) and in individuals referred for HCM genetic testing (Berge KE et al. Clin Genet. 2014;86(4):355-60; Walsh R et al. Genet Med. 2017 02;19(2):192-203). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at